3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 2
1
Status
Completed
3
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Gynecologic
1
Genitourinary
1
Conditions
Ovarian Neoplasms
1
Metastatic Castration Resistant Prostate Cancer
1
Mental Retardation, X-Linked, With Or Without Seizures, Arx-Related
1
Fallopian Tube Neoplasms
1
Interventions
pembrolizumab
37
Carboplatin
31
Cisplatin
30
Paclitaxel
23
Nivolumab
21
Pemetrexed
21
Dexamethasone
18
Gemcitabine
18
Ipilimumab
15
Docetaxel
13
Fluorouracil
13
Capecitabine
12
Rituximab
12
Cyclophosphamide
10
Cytarabine
10
Trastuzumab
9
atezolizumab
9
daratumumab
9
olaparib
9
130-nm albumin-bound paclitaxel
8
Lenalidomide
8
Prednisone
8
durvalumab
8
trastuzumab deruxtecan
8
Bevacizumab
7
Bortezomib
7
Fulvestrant
7
Oxaliplatin
7
Vinorelbine
7
cabozantinib
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Has results
×
Has announcements
×
rucaparib
×
Clear all
NCT02975934
2025-07-25
TRITON3
pharmaand GmbH
Phase 3
Completed
405 enrolled
34 charts
1 FDA
NCT01968213
2023-06-09
ARIEL3
pharmaand GmbH
Phase 3
Completed
564 enrolled
18 charts
1 FDA
NCT02952534
2023-06-09
TRITON2
pharmaand GmbH
Phase 2
Completed
277 enrolled
23 charts
1 FDA